Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
Titel:
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
Auteur:
Robak, Tadeusz Jin, Jie Pylypenko, Halyna Verhoef, Gregor Siritanaratkul, Noppadol Drach, Johannes Raderer, Markus Mayer, Jiri Pereira, Juliana Tumyan, Gayane Okamoto, Rumiko Nakahara, Susumu Hu, Peter Appiani, Carlos Nemat, Sepideh Cavalli, Franco